Keywords: Amgen, Aranesp, Ph III, Heart failure, Singapore, MAb production

Amgen's Aranesp fails in heart patients; to invest $200 million in Singapore

Article | 18 January 2013

Print This

USA-based Amgen (Nasdaq: AMGN), the world’s largest independent biotech firm, announced top-line results of the Phase III Aranesp ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in